Meeting
2022 ASCO Annual Meeting
Management of infliximab-refractory immune checkpoint inhibitor gastrointestinal toxicity: A multicenter case series.
Authors
Catriona Harvey
Royal North Shore Hospital, Sydney, Australia
Catriona Harvey , Kazi Jannatun Nahar , Serigne N. Lo , Tasnia Ahmed , Sheima Farag , Nadia Yousaf , Kate Young , Liselotte Tas , Aafke Meerveld-Eggink , Christian U. Blank , Austin Thomas , Jennifer Leigh McQuade , Bastian Schilling , Douglas Buckner Johnson , Roberto Martin Huertas , Ana Maria Arance , Joanna Lee , Lisa Zimmer , Georgina V. Long , Alexander M. Menzies
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2665)
DOI
10.1200/JCO.2022.40.16_suppl.2665
Abstract #
2665
Poster Bd #
319
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapy.
First Author: Helen Clare Dearden
Poster
2016 ASCO Annual Meeting
Toxicity associated with ipilimumab and nivolumab (Ipi+Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP).
First Author: Claire Frances Friedman
Poster
2023 ASCO Annual Meeting
Phase Ib/II study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combination in metastatic melanoma refractory to prior immune checkpoint inhibitor therapy with and without CNS disease.
First Author: Saya Jacob
Poster
2023 ASCO Annual Meeting
Effect of fecal transplantation on patients’ reported outcome after immune checkpoint inhibitor colitis.
First Author: Yinghong Wang